Dr. Kelly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Ste 8302E
Los Angeles, CA 90089Phone+1 323-865-3950Fax+1 210-450-1150
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2009
University College Cork Faculty of MedicineClass of 2001
Certifications & Licensure
TX State Medical License 2012 - 2026
CA State Medical License 2016 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2011 Oct 01
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Start of enrollment: 2012 Apr 16
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Feb 08
Publications & Presentations
PubMed
- 44 citationsVenetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee
Blood. 2023-03-16 - 152 citationsPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Jatin J. Shah, Andrzej Jakubowiak, Owen A. O'Connor, Robert Z. Orlowski, R. Donald Harvey
Clinical Cancer Research. 2016-01-01 - 23 citationsIndatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R. Kelly, Sikander Ailawadhi, David S. Siegel, Leonard T. Heffner, George Somlo
The Lancet. Haematology. 2021-11-01
Abstracts/Posters
- Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...Kevin R Kelly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)Kevin R Kelly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid NeoplasiaKevin R Kelly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Wm. Kevin Kelly Appointed Chair of Medical Oncology at Thomas JeffersonJanuary 13th, 2023- Enzalutamide Induces Response in Certain Men with Prostate Cancer on Active SurveillanceAugust 5th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
